Oragenics (NYSEAM:OGEN) - Stock Price, News & Analysis

OGEN Stock Overview

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States.

About the company

OGEN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue ($38K)

Does not have a meaningful market cap ($5M)

Oragenics, Inc. Competitors

Scorpius Holdings

NYSEAM:SCPX

US$5.8m

Silo Pharma

NasdaqCM:SILO

US$5.1m

Exicure

NasdaqCM:XCUR

US$4.7m

Xenetic Biosciences

NasdaqCM:XBIO

US$5.9m

Price History & Performance

Summary of all time highs, changes and price drops for Oragenics
Historical stock prices
Current Share Price	US$1.09
52 Week High	US$7.74
52 Week Low	US$1.02
Beta	0.32
1 Month Change	-23.24%
3 Month Change	-77.05%
1 Year Change	-61.07%
3 Year Change	-97.81%
5 Year Change	-96.47%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	OGEN	US Biotechs	US Market
7D	0.9%	1.5%	1.2%
1Y	-61.1%	1.1%	24.7%

Return vs Industry: OGEN underperformed the US Biotechs industry which returned 1.1% over the past year.

Return vs Market: OGEN underperformed the US Market which returned 24.7% over the past year.

Price Volatility

Is OGEN's price volatile compared to industry and market?
OGEN volatility
OGEN Average Weekly Movement	23.0%
Biotechs Industry Average Movement	11.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: OGEN's share price has been volatile over the past 3 months.

Volatility Over Time: OGEN's weekly volatility has increased from 15% to 23% over the past year.

About the Company

Founded	Employees	CEO	Website
1996	5	Mike Redmond	www.oragenics.com

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company’s product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.

Oragenics, Inc. Fundamentals Summary

How do Oragenics's earnings and revenue compare to its market cap?
OGEN fundamental statistics
Market cap	US$4.88m
Earnings (TTM)	-US$20.66m
Revenue (TTM)	US$37.65k

129.7x

P/S Ratio

-0.2x

P/E Ratio

Is OGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OGEN income statement (TTM)
Revenue	US$37.65k
Cost of Revenue	US$15.49m
Gross Profit	-US$15.45m
Other Expenses	US$5.20m
Earnings	-US$20.66m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.61
Gross Margin	-41,040.42%
Net Profit Margin	-54,858.14%
Debt/Equity Ratio	9.9%

How did OGEN perform over the long term?

See historical performance and comparison

OGEN Stock Overview

Rewards

Risk Analysis

Oragenics, Inc. Competitors

NYSEAM:SCPX

US$5.8m

NasdaqCM:SILO

US$5.1m

NasdaqCM:XCUR

US$4.7m

NasdaqCM:XBIO

US$5.9m

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Recent updates

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

Executive Chairman recently bought US$66k worth of stock

Price target decreased to US$2.25

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Price target increased to US$2.25

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Executive Chairman exercised options to buy US$110k worth of stock.

New 90-day high: US$1.30

Oragenics, Inc. Provides Update on Competitive Positioning of Terra CoV-2 Vaccine Against SARS-CoV-2, Expects to File IND in Third Quarter of 2021

New 90-day high: US$0.62

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Insider recently sold US$2.1m worth of stock

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5.25 million.

New 90-day low: US$0.47

New 90-day low: US$0.54

Oragenics, Inc. Announces Receipt of Feedback to Its Type B Pre-Ind Meeting Request from the U.S. Food and Drug Administration

New 90-day low: US$0.56

Oragenics, Inc. (AMEX:OGEN) acquired Noachis Terra Inc. from Joseph Hernandez for $6.6 million.

Shareholder Returns

Price Volatility

About the Company

Oragenics, Inc. Fundamentals Summary

129.7x

-0.2x

Earnings & Revenue